Literature DB >> 7573453

Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach.

H P Parkman1, A P Pagano, M A Vozzelli, J P Ryan.   

Abstract

The aims of this study were to determine regional differences and the mechanism of gastric contractile effects of erythromycin. Rabbit gastric circular muscle strips were studied in vitro. The threshold dose for erythromycin was significantly less and the maximum contraction greater in the antrum (1 microM and 0.9 +/- 0.3 kg/cm2) than in the fundus (10 microM and 0.3 +/- 0.1 kg/cm2). Erythromycin-induced antral contractions were decreased by motilin tachyphylaxis but unaffected by tetrodotoxin, atropine, hexamethonium, or ondansetron. At a subthreshold dose (0.1 microM), erythromycin increased the frequency, but not the amplitude, of bethanechol (10 +/- 3%)-and substance P-induced (13 +/- 5%) phasic antral contractions. This chronotropic effect was inhibited with tetrodotoxin, atropine, or motilin tachyphylaxis. Erythromycin (10 microM) and motilin (1 microM) enhanced the amplitude of substance P-induced tonic fundic contractions by 38 and 32%, respectively, without effect on bethanechol-induced contractions. In summary, erythromycin contracts antral muscle more potently and forcefully than fundic muscle. Erythromycin increases antral contractility by two mechanisms: an inotropic effect acting on smooth muscle motilin receptors, and, at lower doses, a cholinergic chronotropic effect mediated through neuronal motilin receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573453     DOI: 10.1152/ajpgi.1995.269.3.G418

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

1.  Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants.

Authors:  P C Ng; K W So; K S Fung; C H Lee; T F Fok; E Wong; W Wong; K L Cheung; A F Cheng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

Review 2.  Gastroparesis: current diagnostic challenges and management considerations.

Authors:  Shamaila Waseem; Baharak Moshiree; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

3.  Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans.

Authors:  B Coulie; J Tack; T Peeters; J Janssens
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 4.  Prokinetics in diabetic gastroparesis.

Authors:  Reza A Hejazi; Richard W McCallum; Irene Sarosiek
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 5.  The migrating motor complex: control mechanisms and its role in health and disease.

Authors:  Eveline Deloose; Pieter Janssen; Inge Depoortere; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-03-27       Impact factor: 46.802

Review 6.  Erythromycin as a prokinetic agent in preterm neonates: a systematic review.

Authors:  S Patole; S Rao; D Doherty
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05-17       Impact factor: 5.747

7.  The rabbit motilin receptor: molecular characterisation and pharmacology.

Authors:  N B Dass; J Hill; A Muir; T Testa; A Wise; G J Sanger
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

8.  Motilin induces gall bladder emptying and antral contractions in the fasted state in humans.

Authors:  Y C Luiking; T L Peeters; M F Stolk; V B Nieuwenhuijs; P Portincasa; I Depoortere; G P van Berge Henegouwen; L M Akkermans
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

9.  Interaction of insulin with prokinetic drugs in STZ-induced diabetic mice.

Authors:  Mohamed A Fouad Shalaby; Hekma A Abd El Latif; Mostafa E El Sayed
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-05-06

10.  Pharmacokinetic and pharmacodynamic studies of SK-896, a new human motilin analogue, in healthy male volunteers.

Authors:  Yoshiyuki Furuta; Yukiharu Nakayama; Mitsuyoshi Nakashima; Yoshio Suzuki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.